Navigate clinical trials
What is Trial Navigator?
Trial Navigator is a specialized agent in Owkin K that helps pharmaceutical and clinical teams explore the clinical trial landscape using plain-language questions. You ask the way you'd ask a colleague; it interprets the intent, filters a large clinical-trials dataset, and returns the right output: a visual timeline, a data table, a statistical projection, or a direct answer.
Use it to:
Map competitive landscapes across an indication, mechanism of action, or drug class
Track competitor pipelines and development timelines
Answer quantitative questions about the trial landscape (counts, averages, distributions)
Compare trials against a reference trial (e.g. "PFS better than trial X")
Deep-dive a single trial's design assumptions and projected readout times
How it works
You don't need to know the internals to use Trial Navigator, but a quick mental model helps you write better queries. Behind the scenes it:
See it in action
Writing effective queries
Name the therapeutic area / indication (e.g. NSCLC, TNBC, glioblastoma).
Name the mechanism of action or drug class when relevant (PD-1/PD-L1, EGFR TKI, ADC, VEGFR, CLDN18.2).
Name sponsors, drugs, or NCT IDs when you have them.
Add a phase to narrow the development stage (Phase I, II, III, I/II…).
Add a timeframe ("started after 2020", "between 2018 and 2023").
Add thresholds ("enrollment greater than 500", "accrual target of exactly 500").
Use exclusions freely ("excluding Phase I", "excluding breast and prostate cancer").
Ask for top / latest / longest when you want a ranked shortlist ("the 5 most recent…", "longest-running…").
What you can ask
Competitive landscape / list trials
Returns an interactive Gantt chart, a detailed results table, and summary statistics.
Complex multi-filter queries
The tool handles several constraints at once, combining indication, phase, geography, dates, mechanism, and thresholds.
Ranked / "top N" / "latest N" / "longest-running"
Ask for a ranked shortlist instead of the full set.
Aggregate & quantitative questions
For counts, averages, percentages, and "what's covered" questions, the tool answers directly in text, with supporting figures where useful.
Comparative queries (against a reference trial)
The tool can find a reference trial first, then compare the rest of the landscape against it.
Single-trial statistical analysis
Deep-dive the statistical assumptions behind a specific trial's design and projected readout times. Returns a projection plot, predicted median OS/PFS, predicted enrollment duration, and the reference trials used for the prediction.
Understanding the outputs
Gantt chart (timeline)
X-axis: time (years)
Y-axis: individual trials, grouped by phase and sorted by start date
Colour: trial phase; bars show duration with mechanism-of-action abbreviations
Includes both industry-sponsored and publicly/academically sponsored trials.

Results table
A sortable, filterable list of every matching trial: NCT ID (linked to ClinicalTrials.gov), sponsor, phase, indication, drug/mechanism, and key results.

Summary statistics
An automatically computed answer summary, for example total trial count, phase distribution, and top indications represented.

Statistical projection plot
For single-trial analysis: an enrollment curve and survival projections, with the reference trials (by NCT ID) used to generate the predictions.

PowerPoint export
Trial Navigator can export a competitive-landscape view into a PowerPoint slide.
Searchable data fields
Trial Navigator is built on a comprehensive oncology clinical-trials dataset sourced from ClinicalTrials.gov. You can filter and search across the following dimensions.
Identification
NCT ID
ClinicalTrials.gov identifier
Brief Title
Short trial title
Official Title
Full formal trial title
Commercial Name
Sponsor's commercial trial name
Status & timeline
Overall Status
Recruiting, Active Not Recruiting, Completed, Terminated, etc.
Trial Start Date
Date the trial began
Primary Completion Date
Date of primary outcome measurement
Completion Date
Full study completion date
Trial Duration
Duration in days
Design
Study Type
Interventional, Observational
Trial Phase
I, II, III, IV, I/II, II/III, III/IV
Randomization
Whether the trial is randomized
Number of Arms
Count of treatment arms
Group Types
Experimental, Active Comparator, Placebo Comparator, etc.
Sponsors
Private / Industry Sponsors
Pharmaceutical and biotech companies (Pfizer, Roche, AstraZeneca, etc.)
Public / Academic Sponsors
Universities, hospitals, research centers, government agencies
Industry Sponsored
Boolean flag for industry involvement
Enrollment & accrual
Enrollment
Number of participants
Accrual Target
Target number of subjects
Accrual Actual
Actual enrolled subjects
Enrollment Duration
Time to complete enrollment (days)
Geography
Trial Countries
Countries where the trial is conducted
Trial Regions
Regions (North America, Western Europe, Asia, etc.)
Number of Sites
Count of trial sites
Eligibility criteria
Gender
Both, Female Only, Male Only
Age Range
Minimum and maximum age for eligibility
ECOG Status
Performance status requirements (0-4 scale)
Disease Stages
Localized, locally advanced, advanced, metastatic, resectable, unresectable
Disease Paths
Persistent, recurrent, refractory, relapsed, resistant
Lines of Therapy
Prior treatment requirements
Indications (cancer types)
Trial Navigator covers a comprehensive oncology landscape, including:
Solid tumors:
Breast, Lung (NSCLC, SCLC), Colorectal, Pancreas
Melanoma, Renal, Bladder, Prostate
Head/Neck, Esophageal, Gastric, Liver
Ovarian, Endometrial, Cervical
CNS tumors (Glioblastoma, Astrocytoma, Meningioma, etc.)
And many more
Hematological malignancies:
Leukemia (ALL, AML, CML, CLL)
Lymphoma (Hodgkin's, Non-Hodgkin's)
Multiple Myeloma
Myelodysplastic Syndrome
Myeloproliferative Neoplasms
Treatment & intervention
Drug Names
Investigational drug names
Drug Type
ADC, Antibody Bispecific, Antibody Multispecific, Gene Therapy, Small Molecule
Mechanisms of Action
JAK inhibitor, CDK inhibitor, PD-1/PD-L1 inhibitor, etc.
Targets (HGNC)
Gene symbols (KRAS, TP53, BRCA1, EGFR, ERBB2, etc.)
Biomarkers
Biomarkers used in trial selection
Combination Therapy
Whether the trial tests a drug combination
Endpoints
Primary Endpoints
OS, PFS, DUAL, or other
Has OS
Overall Survival as endpoint
Has PFS
Progression-Free Survival as endpoint
Has EFS/DFS/RFS
Event-free, Disease-free, Recurrence-free Survival
Outcomes (actual & predicted)
Objective Response Rate
ORR from trial results
Disease Control Rate
DCR from trial results
Median OS (months)
Actual median overall survival
Median PFS (months)
Actual median progression-free survival
Predicted Median OS
AI-predicted median OS
Predicted Median PFS
AI-predicted median PFS
Predicted Enrollment Duration
AI-predicted time to complete enrollment
Tips & good-to-knows
Last updated
Was this helpful?